MF-438

CAS No. 921605-87-0

MF-438( —— )

Catalog No. M22502 CAS No. 921605-87-0

MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 236 In Stock
2MG 140 In Stock
5MG 215 In Stock
10MG 328 In Stock
25MG 557 In Stock
50MG 779 In Stock
100MG 1079 In Stock
200MG Get Quote In Stock
500MG 2158 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MF-438
  • Note
    Research use only, not for human use.
  • Brief Description
    MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.
  • Description
    MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.
  • In Vitro
    ——
  • In Vivo
    MF-438 exhibits an ED50 between 1 and 3 mg/kg in a mouse model.
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    SCD
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    921605-87-0
  • Formula Weight
    421.44
  • Molecular Formula
    C19H18F3N5OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:62.5 mg/mL (148.30 mM; Need ultrasonic)
  • SMILES
    Cc1nnc(s1)-c1ccc(nn1)N1CCC(CC1)Oc1ccccc1C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Léger S, et al. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett. 2010 Jan 15;20(2):499-502.
molnova catalog
related products
  • AGI-5198

    AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

  • DSM421

    DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.

  • Kakkalide

    Kakkalide is a potent lactate dehydrogenase (LDH) inhibitor, it has anti-inflammatory effects.